Tianjin Pharmaceutical Group's application for marketing approval of formoterol fumarate has been approved, further enriching the company's product portfolio.
Recently, Tianjin Pharmaceutical Group Co., Ltd. received the "Approval Notice for Marketing Application of Formoterol Fumarate" issued by the National Medical Products Administration, granting it market access. Formoterol fumarate is a β2-receptor agonist with bronchodilator, bronchospasm relief, and anti-allergic effects. It is understood that the current market dosage forms mainly include tablets, inhaled solutions, and inhaled powders. Formoterol fumarate inhalation solution is already marke